UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC

Lung cancer (Amsterdam, Netherlands), 2019-01, Vol.127, p.153-163

2019

Volltextzugriff (PDF)

Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer

Journal for immunotherapy of cancer, 2021-03, Vol.9 (3), p.e001865

2021

Volltextzugriff (PDF)

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance

Molecular cancer, 2014-06, Vol.13 (1), p.143-143, Article 143

2014

Volltextzugriff (PDF)

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

Molecular cancer, 2012-12, Vol.11 (1), p.91-91, Article 91

2012

Volltextzugriff (PDF)

Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program

Tumor biology, 2018-11, Vol.40 (11), p.1010428318815047-1010428318815047

2018

Volltextzugriff (PDF)

Molecular Mechanisms Underlying the Antitumor Activity of 3-Aminopropanamide Irreversible Inhibitors of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer

Neoplasia (New York, N.Y.), 2013, Vol.15 (1), p.61-IN18

2013

Volltextzugriff (PDF)

Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer: A meta-analysis

JNCI : Journal of the National Cancer Institute, 2023-01, Vol.115 (1), p.29-42

2023

Volltextzugriff (PDF)

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2016-11, Vol.375 (19), p.1823-1833

2016

Volltextzugriff (PDF)

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2019-12, Vol.20 (12), p.1655-1669

2019

Volltextzugriff (PDF)

Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib

Anti-cancer drugs, 2024-01, Vol.35 (1), p.86

2024

Volltextzugriff (PDF)

PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Clinical lung cancer, 2021-09, Vol.22 (5), p.423-431

2021

Volltextzugriff (PDF)

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA

Oncotarget, 2017-02, Vol.8 (8), p.13611-13619

2017

Volltextzugriff (PDF)

Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis

Anticancer research, 2014-06, Vol.34 (6), p.3185-3188

2014

Volltextzugriff (PDF)

First-Line Chemotherapy Treatment of Advanced Non–Small-Cell Lung Cancer: Does Cisplatin versus Carboplatin Make a Difference?

Journal of thoracic oncology, 2014-11, Vol.9 (11), p.e82-e82

2014

Volltextzugriff (PDF)

PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: the role of salvage chemo-immunotherapy combination

Immunotherapy, 2021-04, Vol.13 (5), p.363-369

2021

Volltextzugriff (PDF)

PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors

Tumori, 2022-02, Vol.108 (1), p.47-55

2022

Volltextzugriff (PDF)

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non–Small Cell Lung Adenocarcinoma

Journal of thoracic oncology, 2017-10, Vol.12 (10), p.e165-e167

2017

Volltextzugriff (PDF)

Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2014-02, Vol.83 (2), p.265-271

2014

Volltextzugriff (PDF)

Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer

Cancer, 2006-12, Vol.107 (12), p.2842-2849

2006

Volltextzugriff (PDF)

CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients

Tumor biology, 2015-08, Vol.36 (8), p.5943-5951

2015

Volltextzugriff (PDF)

Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab

Immunotherapy, 2018-06, Vol.10 (8), p.681-694

2018

Volltextzugriff (PDF)

Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study

Lung cancer (Amsterdam, Netherlands), 2015-11, Vol.90 (2), p.234-242

2015

Volltextzugriff (PDF)

Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report

Clinical lung cancer, 2020-03, Vol.21 (2), p.e45-e48

2020

Volltextzugriff (PDF)

Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed–carboplatin

Lung cancer (Amsterdam, Netherlands), 2012-10, Vol.78 (1), p.92-99

2012

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Aktive Filter

ThemaCarcinoma, Non-Small-Cell Lung - Drug Therapy

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(45)

Sprache

Englisch
(45)

Erscheinungsjahr

n.n

Thema

Humans
(45)
Lung Neoplasms - Drug Therapy
(42)
Life Sciences & Biomedicine
(41)
Science & Technology
(41)
Male
(38)
Oncology
(38)
Aged
(37)
Middle Aged
(37)
Lung Neoplasms - Pathology
(29)
Carcinoma, Non-Small-Cell Lung - Pathology
(28)
Adult
(25)
Aged, 80 And Over
(18)
Treatment Outcome
(17)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(16)
Prognosis
(14)
Biological And Medical Sciences
(13)
Carcinoma, Non-Small-Cell Lung - Genetics
(13)
Chemotherapy
(13)

13 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Lung Cancer
(12)
Clinical Lung Cancer
(3)
Journal Of Thoracic Oncology
(3)
American Journal Of Clinical Oncology
(2)
Cancer
(2)
Immunotherapy
(2)
Molecular Cancer
(2)
Tumor Biology
(2)
Tumori
(2)
Anti-Cancer Drugs
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC

Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial

Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program

Molecular Mechanisms Underlying the Antitumor Activity of 3-Aminopropanamide Irreversible Inhibitors of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer

Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer: A meta-analysis

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib

PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA

Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis

First-Line Chemotherapy Treatment of Advanced Non–Small-Cell Lung Cancer: Does Cisplatin versus Carboplatin Make a Difference?

PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: the role of salvage chemo-immunotherapy combination

PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non–Small Cell Lung Adenocarcinoma

Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)

Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer

CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients

Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab

Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study

Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report

Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed–carboplatin

Aktive Filter

Suchergebnisse filtern